Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by He, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.
Right arrow Articles by He, J.
J Am Soc Nephrol 14:469-477, 2003
© 2003 American Society of Nephrology

Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults

Jing Chen*, Paul Muntner*,{dagger}, L. Lee Hamm*, Vivian Fonseca*, Vecihi Batuman*, Paul K. Whelton*,{dagger} and Jiang He*,{dagger}

*Tulane University School of Medicine and {dagger}School of Public Health and Tropical Medicine, New Orleans, Louisiana.

Correspondence to Dr. Jiang He, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1430 Tulane Avenue SL18. Phone: 504-588-5165; Fax: 504-988-1568;


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ABSTRACT. This study examined the relationship of fasting serum glucose, insulin, C-peptide, glycosylated hemoglobin A (HbA1c), and Homeostasis Model Assessment (HOMA)-insulin resistance to risk of chronic kidney disease (CKD) among 6453 persons without diabetes (fasting glucose <126 mg/dl and not taking diabetes medication) who participated in the Third National Health and Nutrition Examination Survey and were aged 20 yr or older. CKD was defined as an estimated GFR <60 ml/min per 1.73 m2. The prevalence of CKD was significantly and progressively higher with increasing levels of serum insulin, C-peptide, HbA1c, and HOMA-insulin resistance. After adjustment for potential confounding variables, the odds ratio of CKD for the highest compared with the lowest quartile was 4.03 (95% confidence interval [CI], 1.81 to 8.95; P = 0.001), 11.4 (95% CI, 4.07 to 32.1; P < 0.001), 2.67 (95% CI, 1.31 to 5.46; P = 0.002), and 2.65 (95% CI, 1.25 to 5.62; P = 0.008) for serum insulin, C-peptide, HbA1c levels, and HOMA-insulin resistance, respectively. For a one SD higher level of serum insulin (7.14 µU/ml), C-peptide (0.45 {Delta}mol/ml), HbA1c (0.52%), and HOMA-insulin resistance (1.93), the odds ratio (95% CI) of CKD was 1.35 (1.16 to 1.57), 2.78 (2.25 to 3.42), 1.69 (1.28 to 2.23), and 1.30 (1.13 to 1.50), respectively. These findings combined with knowledge from previous studies suggest that the insulin resistance and concomitant hyperinsulinemia are presented in CKD patients without clinical diabetes. Further studies into the causality between insulin resistance and CKD are warranted. E-mail address: jhe@tulane.edu


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Diabetic nephropathy remains the leading cause of end-stage renal disease (ESRD) in western populations (1) and accounts for over 40% of new cases of ESRD each year in the United States (2–4). The prevalence of diabetes has been increasing progressively in the US and other countries, and the number of adults with diabetes in the world is projected to increase to approximately 300 million in the year 2025 (5). As a consequence, diabetic ESRD is expected to become increasingly prevalent in the future (6). Patients with ESRD suffer from poor quality of life and shorter life expectancy compared with individuals of the same age in the general population (3,4). Those with diabetic ESRD have a much less favorable outcome than their counterparts with nondiabetic ESRD (4,7). Prevention of diabetes-related kidney disease is a key to decreasing the societal and personal burden of illness due to ESRD.

Insulin resistance and compensatory hyperinsulinemia have been associated with hypertension, hyperuricemia, increased levels of serum triglyceride, smaller denser LDL particles, circulating plasminogen activator inhibitor, and decreased levels of HDL (8,9). Furthermore, insulin resistance has been an underlying cause of type 2 diabetes and arteriosclerotic vascular disease (10–12). Several small clinical studies have noted insulin resistance in nondiabetic patients with mild renal dysfunction (13–15). However, there are sparse data on the relationship among insulin resistance, compensatory hyperinsulinemia, and the risk of chronic kidney disease (CKD) in nondiabetics.

We took advantage of the large representative sample of US adults who participated in the third National Health and Nutrition Examination Survey (NHANES III) to examine the relationship among glucose, C-peptide, insulin, HbA1c, and insulin resistance index and the risk of CKD.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Participants
NHANES III was conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention between 1988 and 1994. A detailed description of the study participants and methods has been published elsewhere (16). In brief, a stratified multistage probability design was employed to obtain a representative sample of the civilian non-institutionalized US general population (16). The study design included oversampling of those who were very young, elderly, non-Hispanic blacks, and Mexican-Americans to improve the precision of estimates in these groups. A sub-sample of 7832 NHANES III participants who were 20 yr and older were random selected to take part in morning visits at which fasting blood specimens were obtained. Persons without a fasting blood sample (n = 485), those with a missing glucose value (n = 142), and those with kidney failure according to National Kidney Foundation definition of an estimated GFR <15 ml/min per 1.73 m2 (n = 7) were excluded from the current analysis. After the exclusions, we were able to utilize experience from 745 persons with and 6453 persons without diabetes for the main analyses.

Measurements
NHANES III data were collected by administration of a standardized questionnaire during a home interview followed by conduct of a detailed physical examination with collection of blood specimens at a mobile examination center or the participant’s home. Information on a wide variety of sociodemographic, medical history, nutritional history, and family history questions, such as self-reported age, race/ethnicity, gender, years of education completed, history of smoking and hypertension, use of antihypertensive medication, alcohol consumption, and 24-h dietary recall, were obtained during the home interview (16).

BP was measured three times during the home interview and three times during the subsequent evaluation at the mobile examination center by trained observers using a standard protocol (16). BP for an individual participant was calculated as the average of all available systolic and diastolic readings. Hypertension was defined as the presence of a mean systolic BP >=140 mmHg and/or diastolic BP >=90 mmHg and/or use of antihypertensive medication. Body weight and height were measured according to a standard protocol, and body mass index was calculated as an index for obesity.

For NHANES III participants who were assigned to a physical examination during a morning session, a blood sample was collected after an overnight fast of >=8 h. Plasma glucose level was measured with a hexokinase enzymatic reference method (COBAS MIRA; Roche Diagnostics Corporation, Laboratory Systems, Indianapolis, IN), serum insulin level by means of a RIA (Pharmacia Diagnostics, Uppsala, Sweden), C-peptide level by use of a RIA (Bio-Rad Laboratories Inc, Hercules, Calif), and glycosylated hemoglobin concentration by means of ion-exchange HPLC with a glycosylated hemoglobin analyzer system (DIAMAT; Bio-Rad Laboratories Inc, Hercules, CA) at the University of Missouri, Columbia (16,17). Serum total cholesterol was measured enzymatically using a commercially available reagent mixture (Cholesterol/HP; Boehringer Mannheim Diagnostics, Indianapolis, IN) at the Johns Hopkins University Lipid Research Clinic, Baltimore, MD, and creatinine was analyzed by the modified kinetic Jaffe reaction method using a Hitachi 737 analyzer (Boehringer Mannheim Corporation, Indianapolis, IN) (16,17).

Diabetes was defined as a fasting plasma glucose >=126 mg/dl and/or the current use of diabetes medication (18). A Homeostasis Model Assessment (HOMA) was used to evaluate insulin resistance (19). Assuming that normal subjects aged <35 yr with normal weight have an insulin resistance of 1, the values for a patient can be calculated from the fasting concentrations of insulin and glucose using the following formula: fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L)/22.5 (19).

GFR was calculated using the abbreviated equation developed by the Modification of Diet in Renal Disease (MDR) study (20). Estimated GFR = 186.3 x (sCr) - 1.154 x age - 0.203 x (0.742 if female) x (1.21 if black). Serum creatinine level was calibrated for measurement variance between NHANES III and MDRD clinical laboratories (21). Chronic kidney disease was defined as GFR <60 ml/min per 1.73 m2 (6).

Statistical Analyses
Mean values of continuous variables and percentages of categorical variables were calculated by diabetes status. The statistical significance of differences in these characteristics across diabetes status was examined by means of the Z test (continuous variables) and the Wald 2 test (categorical variables) in multivariate regression models after adjustment for age, gender, and race/ethnicity.

The prevalence of CKD was determined by quartile of fasting glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among participants without diabetes. Age, gender, and race- and multivariate-adjusted logistic regression analysis was used to determine the odds ratio of CKD associated with diabetes mellitus and quartile of fasting glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among persons without diabetes. Next, the age-, gender-, race-, and multivariate-adjusted odds ratios of CKD associated with a one SD higher fasting glucose (10.91 mg/dl), insulin (7.14 µU/ml), C-peptide (0.45 {Delta}mol/ml), HbA1c (0.52%), and HOMA-insulin resistance (1.93) were determined. In addition to age, gender, and race, multivariate models included systolic BP, body mass index, total cholesterol, education, physical activity, cigarette smoking, NSAID usage in the past month, and alcohol consumption.

The bivariate relationship on continuous variables was explored by plotting fasting glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance versus estimated GFR, which does not impose any statistical modeling assumptions on the associations. Age-adjusted quantile regression models were also used to assess the relationship of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance versus estimated GFR. These models included fifth order polynomials for age, glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance. Univariate and multivariate linear regression models were used to assess the association between fasting glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance and estimated GFR. Regression coefficients were reported as the difference in estimated GFR (ml/min per 1.73 m2) associated with a one SD increment in fasting glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance. All statistical analyses were performed using Stata software that included functions for the analysis of complex survey data (22).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
General characteristics of the study participants are presented by diabetic status in Table 1. On average, nondiabetic participants were about 17 yr younger than diabetic participants. The percentages of males, non-Hispanic Blacks, and Mexican-Americans were higher, whereas the percentages of persons with a high school education, currently smoking cigarettes, and consuming alcohol were lower in those with versus those without diabetes. Mean systolic BP and body mass index values were significantly higher among persons with diabetes compared with their counterparts without diabetes. Diabetic participants had higher mean levels of plasma glucose, serum insulin, serum C-peptide, HbA1c, and HOMA-insulin resistance compared with nondiabetic participants. Diabetic participants also had a higher prevalence of elevated serum creatinine and CKD compared with their counterparts without diabetes. The percentage of persons with an elevated serum creatinine and CKD was significantly higher in diabetic participants compared with nondiabetic participants. After adjustment for age, race-ethnicity, gender, systolic BP, body mass index, total cholesterol, education, physical activity, cigarette smoking, NSAID usage during the preceding month, and alcohol consumption, the odds ratio of CKD associated with diabetes was 1.82 (95% CI, 1.18 to 2.81, P = 0.007).


View this table:
[in this window]
[in a new window]

  		Table 1. Characteristics of the 7198 study participants by diabetic status
 
Table 2 shows the proportion of participants with CKD by quartile of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among 6453 participants without diabetes. There was a significant positive relationship among higher serum glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance and higher prevalence of CKD.


View this table:
[in this window]
[in a new window]

  		Table 2. Prevalence of chronic kidney disease (GFR <60 ml/min per 1.73 m2) according to quartiles of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among 6453 persons without diabetes
 
After adjustment for age, gender, and race-ethnicity, plasma glucose was no longer significantly associated with the odds of CKD (Table 3). In contrast, after adjustment for age, gender, and race-ethnicity, as well as adjustment for other established risk factors for CKD, a positive, significant, and dose-response relationship was noted among quartile of serum insulin, C-peptide, HbA1c, and HOMA-insulin resistance and the odds of CKD (Table 3). For serum insulin, C-peptide, HbA1c, and HOMA-insulin resistance, the multivariate-adjusted odds ratios of CKD for nondiabetic participants with the highest compared with the lowest quartile were 4.03 (95% CI, 1.81 to 8.95; P = 0.001), 11.4 (95% CI, 4.07 to 32.1; P < 0.001), 2.67 (95% CI, 1.31 to 5.46; P = 0.002), and 2.65 (95% CI, 1.25 to 5.62; P = 0.008), respectively (Table 3).


View this table:
[in this window]
[in a new window]

  		Table 3. Age, gender, and race/ethnicity- or multivariate-adjusted odds ratios of chronic kidney disease according to quartiles of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among 6453 persons without diabetesa
 
Age-, gender-, race/ethnicity-, and multivariate-adjusted odds ratios of CKD associated with a one SD higher level of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among nondiabetic participants are presented in Table 4. Plasma glucose was not significantly associated with the odds of CKD, whereas serum insulin, C-peptide, HbA1c, and HOMA-insulin resistance were all positively and significantly associated with a higher odds of CKD.


View this table:
[in this window]
[in a new window]

  		Table 4. Age, gender, and race/ethnicity- or multivariate-adjusted odds ratios of chronic kidney disease associated with one SD higher level of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among 6453 persons without diabetes
 
The shapes of the association between fasting insulin, C-peptide, HbA1c, and HOMA-insulin resistance versus estimated GFR as a continuous variable among nondiabetic participants are displayed without any parametric assumptions in Figure 1. There was an inverse association between these variables and estimated GFR, which was noticeable even across normal values of renal function. The slope of estimated GFR on C-peptide was much steeper than that on serum insulin. In linear regression analyses, fasting insulin, C-peptide, HbA1c, and HOMA-insulin resistance were inversely and significantly associated with estimated GFR (Table 5). After adjustment for potential confounding variables, a 7.14 µU/ml higher level of insulin was associated with a 1.51 ml/min per 1.73 m2 lower estimated GFR, a 0.45 {Delta}mol/ml higher level of C-peptide was associated with a 4.27 ml/min per 1.73 m2 lower estimated GFR, a 0.52% higher level of HbA1c was associated with a 2.86 ml/min per 1.73 m2 lower estimated GFR, and a 1.93 unit higher level of HOMA-insulin resistance was associated with a 1.71 ml/min per 1.73 m2 lower estimated GFR.



View larger version (51K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Scatter plot of insulin, C-peptide, glycosylated hemoglobin A (HbA1c), and Homeostasis Model Assessment (HOMA)-insulin resistance versus estimated GFR. Lines represent the age-adjusted median (top line) and fifth percentile (bottom line) of estimated GFR using a fifth-order polynomial for each independent variable (i.e., insulin, C-peptide, HbA1c, and HOMA-insulin resistance).

 

View this table:
[in this window]
[in a new window]

  		Table 5. Age, gender, and race/ethnicity or multivariate-adjusted changes of GFR associated with one SD higher level of glucose, insulin, C-peptide, HbA1c, and HOMA-insulin resistance among 6453 persons without diabetes
 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The present study identified a strong, positive, significant, and dose-response relationship among insulin resistance, insulin level, and risk of CKD among nondiabetic participants. This relationship was independent of age, gender, race, and other potential risk factors for CKD, such as BP, obesity, total cholesterol, education, physical activity, cigarette smoking, NSAID use, and alcohol consumption. These findings are noteworthy because they are based on a large, representative sample of the US general population. In addition, careful measures of study exposure and outcome variables allowed for precise estimation of the association. Numerous potentially confounding covariates were measured and adjustment for their effects on risk of CKD was taken into account in the present study.

Certain limitations should be considered in the interpretation of our findings. First, the cross-sectional study design used in NHANES III hinders the ability to draw inferences regarding causality among insulin resistance, hyperinsulinemia, and CKD. For instance, our findings do not allow one to determine whether insulin resistance and concomitant hyperinsulinemia contribute to the initiation or progression of CKD, whether impaired renal function contributes to the development of insulin resistance, or whether insulin resistance is merely a marker for other causes of CKD. Prospective cohort studies or mechanistic clinical studies may provide a better context for answering these questions.

Second, although the liver is the major site for insulin degradation, the kidney plays an essential role in the clearance and degradation of circulating insulin (23,24). In addition, experiments in laboratory animals and human subjects have indicated that the kidney plays an important role in glucose metabolism (25,26). Animal and human studies indicate that acute renal failure results in a reduction in the systemic removal of insulin (27). Therefore, the elevated level of serum insulin and C-peptide observed in our study in CKD patients may be a consequence of a decline in renal function. However, patients with kidney failure were excluded from our analysis. In addition, our data indicate that both serum insulin and plasma glucose levels are increased in patients with CKD, which suggests the presence of insulin resistance among these patients. A reduced clearance of insulin in acute renal failure patients has been associated with a decrease in levels of blood glucose (27). Furthermore, using a more precise method for measurement of insulin resistance (minimal-model technique), insulin resistance has been documented in nondiabetic CKD patients (13,14). In these studies, plasma insulin levels were highly correlated with measured insulin resistance (13,14).

Finally, serum creatinine levels and calculated GFR were used to identify and classify kidney disease in our study. Although inulin or iothalamate clearance techniques may provide a more sensitive estimate of renal function, serum creatinine has been used widely in large epidemiologic studies and in clinical practice for estimation of renal function. As such, the findings from our study are applicable to clinical and public health practice settings.

Diabetes has been identified as a major underlying cause of ESRD in the US population (1–4). Several prospective cohort studies have documented that diabetes is associated with an increased risk of diabetic and nondiabetic ESRD (28–31). Clinical trials have also demonstrated that intensive glycemic control slows the progression of diabetic nephropathy in both type 1 and type 2 diabetic patients (32–34). Our data indicate that glycosylated hemoglobin A, an index of long-term glycemic level, is linearly related to the risk of CKD in persons without diabetes. In our study, a HbA1c level greater than or equal to 5.7% was associated with an elevated risk of CKD. These findings support the notion that intensive glycemic control in diabetics as well as a reduction of glycemic level in persons with an impaired fasting glucose may be important strategies for primary prevention of CKD and slowing the progression of CKD.

Epidemiologic studies have demonstrated that insulin resistance and concomitant hyperinsulinemia play a central role in the development of arteriosclerotic vascular disease (9,12). Insulin resistance has been associated with type 2 diabetes, hypertension, central obesity, and dyslipidemia, all of which are important risk factors for CKD (28–31,35–38). In addition, clinical studies have indicated that a greater degree of insulin resistance may predispose to renal injury by worsening renal hemodynamics through the elevation of glomerular filtration fraction and resultant glomerular hyperfiltration among hypertensives (39).

There are sparse data on the relationship between insulin resistance and CKD in nondiabetic patients. Several small clinical studies have suggested that insulin resistance might be present in kidney disease patients without diabetes (13–15). Vareesangthip et al. (13) found that insulin sensitivity was significantly lower and fasting plasma insulin was significantly higher in 15 adult polycystic kidney disease patients compared with 20 age- and sex-matched subjects with normal renal function. Fliser et al. (14) examined 29 patients with IgA glomerulonephritis, 21 patients with adult polycystic kidney disease in different stages of renal failure, and 16 healthy age-matched controls. Insulin sensitivity (minimal-model technique) was significantly lower and plasma insulin concentration was significantly higher in the kidney disease patients compared with their matched controls. Insulin sensitivity was not significantly different in patients with different underlying causes of renal disease and was similar in renal patients with a GFR within the normal range, mild to moderate renal failure, or advanced renal failure (14). These data suggest that insulin resistance and concomitant hyperinsulinemia are present early in the course of kidney disease, irrespective of underlying cause. DeFronzo et al. (40) examined insulin sensitivity with the euglycemic insulin clamp technique in 17 patients with chronic renal failure and 36 control subjects. They found that insulin-mediated glucose metabolism was reduced by 47%, whereas splanchnic glucose production was similar in the patients with renal failure compared with the controls. Their results suggest that insulin-mediated glucose uptake by the liver is normal in persons with chronic renal failure, and tissue insensitivity to insulin is the primary cause of insulin resistance in patients with CKD (40).

Several epidemiologic studies have reported a positive relationship between insulin resistance and the risk of microalbuminuria in nondiabetic patients (41,42). In the Insulin Resistance Atherosclerosis Study, Mykkanen et al. (41) examined the relationship of insulin sensitivity, estimated by a frequently sampled intravenous glucose tolerance test and the minimal model and fasting plasma insulin concentration, to microalbuminuria in a cross-sectional study of 982 nondiabetic patients aged 40 to 69 yr. They reported that decreased levels of insulin sensitivity were related to an increased prevalence of microalbuminuria (41). Fujikawa et al. (42) conducted a 6-yr prospective study to examine the relationship between insulin resistance and risk of microalbuminuria in 116 nondiabetic Japanese Americans living in Hawaii. Their study indicated that fasting insulin levels and HOMA-insulin resistance were significantly higher in participants who developed microalbuminuria or proteinuria during follow-up compared with those who did not. They concluded that insulin resistance appeared earlier than the appearance of microalbuminuria (42).

Our findings of a positive and significant association among insulin resistance, hyperinsulinemia, and kidney disease in nondiabetic patients have both clinical and public health implications. First, they suggest that it may be beneficial to detect and treat insulin resistance and concomitant hyperinsulinemia in nondiabetic patients with CKD. Second, they suggest that a more aggressive approach to reducing insulin resistance in individual patients and in populations would substantially lower the risk of CKD. Many lifestyle modification measures, such as a reduction in dietary fat intake and an increase in physical activity, have been demonstrated to reduce insulin resistance.

In conclusion, our study documents the presence of a strong, positive, independent, and dose-response relationship between insulin resistance and CKD among nondiabetic patients. These findings combined with knowledge from previous studies suggest that the insulin resistance and concomitant hyperinsulinemia are presented in CKD patients without clinical diabetes. Detection and treatment of insulin resistance should be considered even in nondiabetic patients with CKD. Prevention and treatment of insulin resistance in the community might substantially reduce the societal burden of CKD. Further studies are warranted to establish the causal relationship between insulin resistance and CKD.


   Acknowledgments
 
This study was supported partially by a grant (U01 DK60963) from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, MD.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Parving HOR, Ritz E: Diabetic nephropathy. In: The Kidney, 6th edition, edited by Brenner BM, Levine S, Philadelphia, WB Saunders, 2000, pp 1731
  2. American Diabetes Association: Diabetic nephropathy. Diabetes Care 25 [suppl 1]: 585–589, 2002
  3. He J, Whelton PK: Epidemiology of end-stage renal disease. In: International Handbook of Renal Disease, edited by Brenner BM, Kurokawa K, Haslemere, Euromed Communications Ltd, 1999, pp 1–14
  4. US Renal Data System, USRDS 2001 Annual Data Report: Atlas of end-stage renal disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
  5. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431, 1998[Abstract]
  6. National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 [suppl 2]: S32–33, 2002[CrossRef]
  7. Biesenbach G, Hubmann R, Grafinger P, Stuby U, Eichbauer-Sturm G, Janko O: 5-year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched nondiabetic patients with end-stage renal disease from a single dialysis center from 1991 to 1997. Diabetes Care 23: 1860–1862, 2000[Free Full Text]
  8. Lebovitz HE: Insulin resistance: Definition and consequences. Exper Clin Endocrinol Diabetes 109 [Suppl 2]: S135–148, 2001[CrossRef]
  9. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473–486, 1995[Abstract/Free Full Text]
  10. Boden G: Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clinics North Amer 30: 801–815, 2001
  11. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 113: 909–915, 1990
  12. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Inves 106: 453–458, 2000[Medline]
  13. Vareesangthip K, Tong P, Wilkinson R, Thomas TH: Insulin resistance in adult polycystic kidney disease. Kidney Int 52: 503–508, 1997[Medline]
  14. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Titz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343–1347, 1998[CrossRef][Medline]
  15. Hjelmesaeth J, Hartmann A: Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dialysis Transplant 14: 2521–2522, 1999[Free Full Text]
  16. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey 1988–94. Vital Health Stat 32: 1–407, 1994
  17. National Center for Health Statistics. The Third National Health and Nutrition Examination Survey: (NHANES III 1988–94). Reference Manuals and Reports (CD-ROM). Hyattsville, MD, National Center for Health Statistics, 1996
  18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25: 5S–20S, 2002[CrossRef]
  19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and {beta}-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412–419, 1985[CrossRef][Medline]
  20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470, 1999[Abstract/Free Full Text]
  21. Coresh J, Astor BC, Mcquillan G, Kusek J, Greene T, Lente FV, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920–929, 2002[CrossRef][Medline]
  22. StataCorp: Stata Statistical Software: Release 5.0. College Station, TX, Stata Corporation, 1997
  23. Rubenstein AH, Mako ME, Horwitz DL: Insulin and the kidney. Nephron 15: 306–326, 1975[Medline]
  24. Cianciaruso B, Sacca L, Terracciano V, Marcuccio F, Orofino G, Petrone A, Andreucci VE, Kopple JD: Insulin metabolism in acute renal failure. Kidney Int 32: S109–S112, 1987
  25. Cersosimo E, Judd RL, Miles JM: Insulin regulation of renal glucose metabolism in conscous dogs. J Clin Invest 93: 2584–2589, 1994
  26. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J: Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 96: 2528–2533, 1995
  27. Cianciaruso B, Sacca L, Terracciano V, Marcuccio F, Orofino G, Petrone A, Andreucci VE, Kopple JD: Insulin metabolism in acute renal failure. Kidney Int 32: S109–S112, 1987
  28. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ: Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278: 2069–2074, 1997[Abstract]
  29. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335: 1636–1642, 1996[Abstract/Free Full Text]
  30. Krolewski M, Eggers PW, Warram JH: Magnitude of end-stage renal disease in IDDM: A 35-year follow-up study. Kidney Int 50: 2041–2046, 1996[Medline]
  31. Humphrey LL, Ballard DJ, Frohnert P, Chu C-P, O’Fallon M, Palumbo PJ: Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Intern Med 111: 788–796, 1989
  32. Reichard P, Nilsson BY, Rosenqvist U: The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304–309, 1993[Abstract/Free Full Text]
  33. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993[Abstract/Free Full Text]
  34. UK prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998[CrossRef][Medline]
  35. Whelton PK, Perneger TV, He J, Klag MJ: The role of blood pressure as a risk factor for renal disease: A review of the epidemiologic evidence. J Human Hypertens 10: 683–689, 1996[Medline]
  36. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13–18, 1996[Abstract/Free Full Text]
  37. Iseki K, Ikemiya Y, Fukiyama K: Predictors of end-stage renal disease and body mass index in a screened cohort. Kidney Int 63: S169–S170, 1999
  38. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58: 293–301, 2000[CrossRef][Medline]
  39. Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR: Insulin resistance, elevated glomerular filtration, and renal injury. Hypertension 28: 127–132, 1996[Abstract/Free Full Text]
  40. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J, Insulin resistance in uremia. J Clin Invest 67: 563–568, 1981
  41. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 47: 793–800, 1998[Abstract]
  42. Fujikawa R, Okubo M, Egusa G, Kohno N: Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow-up study. Diabetes Res Clin Pract 53: 99–106, 2001[CrossRef][Medline]
Received for publication September 7, 2002. Accepted for publication October 18, 2002.




This article has been cited by other articles:


Home page
 CJASNHome page
S. Kobayashi, M. Oka, K. Maesato, R. Ikee, T. Mano, M. Hidekazu, and T. Ohtake
Coronary Artery Calcification, ADMA, and Insulin Resistance in CKD Patients
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1289 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Nerpin, U. Riserus, E. Ingelsson, J. Sundstrom, M. Jobs, A. Larsson, S. Basu, and J. Arnlov
Insulin Sensitivity Measured With Euglycemic Clamp Is Independently Associated With Glomerular Filtration Rate in a Community-Based Cohort
Diabetes Care, August 1, 2008; 31(8): 1550 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Shankar, C. Leng, K. S. Chia, D. Koh, E. S. Tai, S. M. Saw, S. C. Lim, and T. Y. Wong
Association between body mass index and chronic kidney disease in men and women: population-based study of Malay adults in Singapore
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1910 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 Age AgeingHome page
M. Kanauchi, K. Kanauchi, T. Inoue, K. Kimura, and Y. Saito
Insulin sensitivity and beta-cell function in older Japanese adults without diabetes
Age Ageing, May 1, 2008; 37(3): 330 - 333.
[Full Text] [PDF]

Home page
 CJASNHome page
C. Lorenzo, S. D. Nath, A. J.G. Hanley, H. E. Abboud, and S. M. Haffner
Relation of Low Glomerular Filtration Rate to Metabolic Disorders in Individuals without Diabetes and with Normoalbuminuria
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 783 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. K. Choi and E. S. Ford
Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey
Rheumatology, May 1, 2008; 47(5): 713 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M L. Trirogoff, A. Shintani, J. Himmelfarb, and T A. Ikizler
Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3 4 chronic kidney disease patients
Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1642 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Cardiovascular DiseaseHome page
A. Whaley-Connell, B. S. Pavey, K. Chaudhary, G. Saab, and J. R. Sowers
Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 27 - 35.
[Abstract] [PDF]

Home page
 CJASNHome page
A. Rashidi, A. Ghanbarian, and F. Azizi
Are Patients Who Have Metabolic Syndrome without Diabetes at Risk for Developing Chronic Kidney Disease? Evidence Based on Data from a Large Cohort Screening Population
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 976 - 983.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
E. Ritz
Metabolic Syndrome: An Emerging Threat to Renal Function
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 869 - 871.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. F. Crutchlow, B. Robinson, B. Pappachen, N. Wimmer, A. J. Cucchiara, D. Cohen, and R. Townsend
Validation of Steady-State Insulin Sensitivity Indices in Chronic Kidney Disease
Diabetes Care, July 1, 2007; 30(7): 1813 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. H. Oterdoom, A. P. J. de Vries, R. T. Gansevoort, P. E. de Jong, R. O. B. Gans, S. J. L. Bakker, and for the PREVEND Study Group
Fasting insulin modifies the relation between age and renal function
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1587 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
I. M. Wahba and R. H. Mak
Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Kaartinen, J. Syrjanen, I. Porsti, A. Harmoinen, A. Pasternack, H. Huhtala, O. Niemela, and J. Mustonen
Insulin resistance and the progression of IgA glomerulonephritis
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 778 - 783.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas
Insulin Induces Renal Vasodilation, Increases Plasma Renin Activity, and Sensitizes the Renal Vasculature to Angiotensin Receptor Blockade in Healthy Subjects
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 944 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Ryu, Y. Chang, D.-I. Kim, W. S. Kim, and B.-S. Suh
{gamma}-Glutamyltransferase as a Predictor of Chronic Kidney Disease in Nonhypertensive and Nondiabetic Korean Men
Clin. Chem., January 1, 2007; 53(1): 71 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Kanauchi, K. Kanauchi, K. Kimura, T. Inoue, and Y. Saito
Associations of chronic kidney disease with the metabolic syndrome in non-diabetic elderly
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3608 - 3609.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. G. de Vinuesa, M. Goicoechea, J. Kanter, M. Puerta, V. Cachofeiro, V. Lahera, F. Gomez-Campdera, and J. Luno
Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S206 - S212.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. F. Fried, R. Katz, M. J. Sarnak, M. G. Shlipak, P. H.M. Chaves, N. S. Jenny, C. Stehman-Breen, D. Gillen, A. J. Bleyer, C. Hirsch, et al.
Kidney Function as a Predictor of Noncardiovascular Mortality
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3728 - 3735.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. S. Fox, M. G. Larson, E. P. Leip, J. B. Meigs, P. W.F. Wilson, and D. Levy
Glycemic Status and Development of Kidney Disease: The Framingham Heart Study
Diabetes Care, October 1, 2005; 28(10): 2436 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Kramer and M. E. Molitch
Screening for Kidney Disease in Adults With Diabetes
Diabetes Care, July 1, 2005; 28(7): 1813 - 1816.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Kurella, J. C. Lo, and G. M. Chertow
Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2134 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. R. Sedor and J. R. Schelling
Association of Metabolic Syndrome in Nondiabetic Patients with Increased Risk for Chronic Kidney Disease: The Fat Lady Sings
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1880 - 1882.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Becker, F. Kronenberg, J. T. Kielstein, H. Haller, C. Morath, E. Ritz, D. Fliser, and for the MMKD Study Group
Renal Insulin Resistance Syndrome, Adiponectin and Cardiovascular Events in Patients with Kidney Disease: The Mild and Moderate Kidney Disease Study
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1091 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. Lau, P.-O. Carlsson, P.S. Leung, C. Wolfrum, E. Asilmaz, E. Luca, J.M. Friedman, M. Stoffel, J.C. Verhave, H.L. Hillege, et al.
Why Less Diabetes with Blockade of the Renin-Angiotensin System?: Evidence for a Local Angiotensin-Generating System and Dose-Dependent Inhibition of Glucose-Stimulated Insulin Release by Angiotensin II in Isolated Pancreatic Islets. Diabetologia 47: 240-248, 2004
J. Am. Soc. Nephrol., March 1, 2005; 16(3): 567 - 573.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. P. Bagby
Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease?
J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2775 - 2791.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. Chen, P. Muntner, L. L. Hamm, D. W. Jones, V. Batuman, V. Fonseca, P. K. Whelton, and J. He
The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults
Ann Intern Med, February 3, 2004; 140(3): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
E Ritz
Minor renal dysfunction: an emerging independent cardiovascular risk factor
Heart, September 1, 2003; 89(9): 963 - 964.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)